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SUMMARY 
Kidneys were transplanted in mongrel dogs so that renal venous drainage was into 
the portal system of the hosts. Thirty-one recipients were not treated, 11 were given 
one dose of 3 mg of azathioprine per kg, and 11 were given 2 mg of azathioprine per 
day. Survival was not statistically increased compared with that in three comparable 
series in which renal venous drainage was into the vena cava, nor were the histopath-
ological findings favorably altered in the "portal" kidneys. The injection of semisoluble 
antigen into the portal vein at the same time as renal transplantation at the caval site, 
had an effect no different from that ifthe antigen were given systemically during caval 
site transplantation. The conclusion that drainage of grafts into the portal vein was 
not beneficial was reached in 20 pigs evenly divided between the portal and vena caval 
sites, and in 12 pairs of dog to pig or pig to dog xenografts. Thus, none of these experi-
ments has identified an advantage of antigen delivery into the portal as opposed to the 
systemic venous system. 
There have been conflicting reports about 
whether or not rejection is reduced in homo-
grafts transplanted so that their venous drain-
age is into the portal circulation and then 
through the liver. Consequently, the question 
of portal site privilege, with or without azathio-
prine treatment, was examined again in mon-
grel dogs and in pigs using a kidney transplant 
model. In addition, the effect of donor semisolu-
ble splenic antigen given via the portal versus 
systemic routes upon canine renal homograft 
survival was tested. 
MATERIALS AND METHODS 
Dog Homotransplantation 
Randomly selected mongrel dogs that 
weighed 9 to 27 kg were operated upon with 
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sodium pentobarbital anesthesia supplemented 
with phencyclidine hydrochloride and succinyl 
choline. Experiments were set up with weight-
matched pairs. After bilateral nephrectomy, 
each dog received a kidney of its partner in the 
right subhepatic space (Fig. 1). The left kidney 
was usually used as the homograft, but ifit had 
a multiple arterial supply, the donor right kid-
ney was used instead. Mter removal, the kid-
neys were flushed free of blood with cold lac-
tated Ringer's solution. The postoperative 
course was monitored by serial measures of 
blood urea nitrogen. 
All animals that did not live a full 5 days 
were excluded from the final analyses, since the 
early deaths were almost always associated 
with technical accidents, acute respiratory 
complications, intussusception, massive infec-
tion, or hemorrhage. The number of experi-
ments to obtain 53 completed portal site experi-
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FIGURE 1. Experimental models. A, Left kidney of canine donor is placed in the recipient right renal fossa 
with renal venous drainage into the inferior vena cava. B, Same as A but with renal drainage into the portal 
vein. 
ments was 80. The number of experiments to 
obtain 53 systemic site experiments was 84. The 
majority of discarded experiments in both por-
tal and systemic outflow models was when aza-
thioprine was given chronically. 
For statistical analysis, credit for duration of 
survival of a given animal was limited to 40 
days. The autopsy tissues were fixed in 10% 
formalin. Light microscopic criteria of rejection 
were used that have been described in past 
publications (22). 
The experimental groups are outlined in Ta-
ble 1. In groups 1, 3, and 5, the graft renal 
artery was anastomosed to the recipient renal 
artery, the renal vein was drained into the 
inferior vena cava, and end to end ureteroure-
terostomy was performed (Fig. lA). In groups 
2, 4, and 6, the same technique was used, ex-
cept that the end of the renal vein was anasto-
mosed to the side of the superior mesenteric or 
portal vein (Fig. IB). When used, azathioprine 
was given i. v., and in groups 5 and 6 conversion 
was made to the oral route as soon as the dogs 
. ate. 
Dog Antigen Infusion and Renal Homotrans-
plantation 
Semisoluble antigen was prepared from the 
spleen of a mongrel donor according to the 
method of Brent and Kilshaw (4), as they modi-
fied it from the method of Medawar (19), and 
suspended in 400 ml of heparinized lactated 
TABLE 1. Experimental groups with canine renal 
transplantation 
Azathio- Daily 
No. prine day azathio-Se- Renal venous prine 
ries of drainage of opera- postoper. dogs tion 
(mg/kg) ative (mg/kg) 
1 32 Vena cava None None 
2 31 Portal None None 
3 11 Vena cava 3 None 
4 11 Portal 3 None 
5 10 Vena cava 3 2 
6 11 Portal 3 2 
Ringer's solution. The following day, the donor 
kidneys were removed at reoperation and one 
each was transplanted to the vena caval site 
(Fig. lA) of two mongrel recipients. As the 
transplantation was being performed, one-half 
(200 ml) of the heparin containing semisoluble 
antigen suspension was infused into the jugular 
vein in control animals or into a mesenteric 
vein tributary in the test animals. Thus, each 
dog received the antigen equivalent of one-half 
a spleen. The mg wet spleen tissue per kg recip-
ient was usually about 1,600 mg, but this var-
ied considerably. 
No immunosuppression was given. The same 
criteria were used to judge the results as de-
scribed in the preceding section. To obtain 15 
dogs with survival for at least a full 5 days (6 
with systemic and 9 with portal antigen) 25 
experiments were necessary. 
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Pig Homotransplantation 
Landrace and large white pigs weighing 9 to 
14 kg were used, with random donor recipient 
pairing. The conditions of anesthesia and care 
were essentially the same as with the dogs, 
except for appropriate diet adjustments. Sur-
vival for 5 full days was also requisite for inclu-
sion in the final analyses. To obtain 10 complete 
portal site experiments, 13 transplantations 
were required. For 10 vena caval experiments, 
15 transplantations were done. The most com-
mon causes of the 8 deaths before 5 days were 
thrombosis of the renal artery (4 examples) and 
pulmonary consolidation (2 examples). 
Previously described surgical techniques 
were used (17,18). These were similar to those 
shown for the dog (Fig. 1), with two common 
deviations. First, arterialization was usually 
by anastomosis of a Carrel patch, or an aortic 
graft to the recipient aorta. In portal site exper-
iments, donor vena cava homografts were fre-
quently used to bridge from the renal vein to 
the portal vein. Usually, one donor was used for 
two recipients; one of these kidneys was placed 
at the portal and the other at the vena caval 
sites. All grafts were cooled with the same infu-
sion technique as was used for the dogs. 
Heterotransplantation 
Acute experiments were performed with the 
same techniques as above by transferring pig 
kidneys to dogs in three pairs of experiments 
and dog kidneys to pigs in nine pairs. With one 
member of a pair, venous outflow was directed 
by anastomosis into the vena cava and with the 
other member, the anastomosis was to the por-
tal vein. The outcome was judged by the gross 
appearance of the heterografts at successive 
times, by evaluation of serial biopsies, and by 
the volume of urine output. 
RESULTS 
Dog Homotransplantation 
No treatment. About one-fifth of the 32 dogs 
of group 1 with the systemic renal venous 
drainage survived for 2 weeks or longer. Two 
animals lived more than 1 month and one sur-
vived for 46 days. Similar results were obtained 
in the 31 animals of group 2 with renal venous 
drainage into the portal vein. Two of these dogs 
had survival of more than 1 month and one 
lived for 4 months (Fig. 2). The differences be-
tween groups 1 and 2 were not statistically 
significant. 
There was essentially no difference in the 
histopathological findings in the homografts of 
groups 1 and 2 (Table 2). 
One dose of azathioprine. A single dose of i. v. 
azathioprine slightly increased survival both in 
animals with systemic (group 3) and portal 
(group 4) venous drainage (Fig. 3), but this 
improvement was not statistically significant. 
There were no significant differences between 
groups 3 and 4. The only animal still alive at 40 
days died after 44 days. The graft of that dog 
had systemic renal vein drainage. 
Histopathologically, groups 3 and 4 were in-
distinguishable (Table 2). 
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FIGURE 2. Portal versus systemic renal transplantation in untreated mongrel dogs. 
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TABLE 2. Pathological findings in canine renal homograftsa 
No. in group 
Rejection 
Total 
Cellular only 
Cellular + humoral 
Normal 
Portal vein thrombosis; no rejection 
Cortical necrosis; no rejection 
Renal artery thrombosis; infarction 
" The groups are defined in Table 1. 
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FIGURE 3. Portal versus systemic renal trans-
plantation in dogs with one dose of 3 mg of aza-
thioprine per kg on the day of operation. 
Chronic azathioprine. The survival of dogs in 
group 6 with portal venous drainage of the 
transplants was not significantly different from 
that of the group 5 animals with systemic 
drainage (Fig. 4), and both were slightly better 
than untreated controls. One of the portal site 
animals lived for 49 days. 
Histopathologically, a protective effect of 
azathioprine was evident in groups 5 and 6 in 
that one-third of the homografts in each group 
was normal (Table 2). 
Dog Antigen Infusion and Renal Transplanta-
tion 
The administration of semi soluble antigen by 
the portal and vena caval routes at the same 
time as orthotopic renal transplantation did not 
significantly influence survival, which was 
11.78 ± 6.26 (SD) days after the portal infusion 
and 12.67 ± 2.24 (SD) days after systemic infu-
sion. 
The histopathological findings were essen-
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FIGURE 4. Portal versus systemic renal trans-
plantation in dogs with chronic azathioprine treat-
ment of low doses. 
tially the same in the two groups (Table 3). 
Pig Homotransplantation 
The survival was almost identical to trans-
plantation to the inferior vena caval outflow 
site versus the portal site (Fig. 5). One animal 
in each group lived for about 1 month. The 
histopathological changes were almost the 
same in the two groups (Table 4). 
H eterotransplantatio n 
No gross differences in appearance or urine 
production were noted between transplantation 
at the portal and vena caval sites with either 
the pig to dog transplantation in which rejec-
tion occurred in a few min, or with the milder 
dog to pig transplantations in which rejection 
occurred after 30 min to 4 hr. 
In the pig to dog renal xenografts, general-
ized and diffuse obstruction of all of the glomer-
ular capillaries by aggregated platelets and 
272 TRANSPLANTATION Vol. 24, No.4 
TABLE 3. Histopathological findings in 
orthotopically placed dog renal homografts after 
intraoperative infusion of semisoluble antigen via 
the portal vein and inferior vena caval routes 
Portal Inferior 
vein vena cava 
Total homografts 9 6 
Rejection 
Total 7 6 
Cellular only 1 1 
Cellular + humoral 6 5 
Normal 0 
Renal artery thrombosis; 0 
infarction 
NO TREATMENT 
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FIGURE 5. Portal versus systemic renal trans 
plantation in untreated pigs. 
TABLE 4. Histopathological findings in pig kidney 
homografts after transplantation to the portal vein 
or inferior vena caval sites 
Portal Inferior 
vein vena cava 
Total homografts 10 10 
Rejection 
Total 10 10 
Cellular 4 2 
Cellular + humoral 6 8 
Normal 0 0 
clumped red blood cells was present 10 mm 
after transplantation. 
By contrast, most of the dog to pig renal 
xenografts appeared to be normal by light mi-
croscopy at this time, although electron micros 
copy did reveal early platelet aggregation. 
About 20 min later, however, there was obvious 
focal and segmental blockage of the glomerular 
capillaries by aggregated platelets and clumped 
red blood cells. These changes progressed and 
neutrophil polymorphonuclear leukocytes be-
came prominent in the lesions, until by 2 hr 
after transplantation, all of the glomerular cap-
illary loops were occluded. There were varia-
tions in the speed with which these events oc-
curred in individual animals, but there were no 
significant histopathological differences be-
tween the grafts with venous outflow into the 
portal vein and those with systemic venous 
drainage. 
DISCUSSION 
Studies in the last 15 years have suggested or 
demonstrated that there is a reduced response 
to antigens that are introduced into the portal 
as compared with the systemic venous system 
(2,6, 7,10,14,20,24,25). Partial removal of 
the antigens by the liver and thus a diminished 
host reaction to their presence has been the 
most common explanation. Alternatively, the 
portal injection could have contributed to toler-
ance induction (2,8,13,16). Pursuant to such 
reports, it was natural in a number of laborato-
ries to test whether there was an immunologi-
cal advantage for kidneys (1,11,12,15,17,18, 
23), hearts (3), pancreatic islets (9, 26), and 
parathyroid cells (21) transplanted into the 
portal circulation or liver. 
The results have been variable. In rats, all 
reports have described a protective effect at the 
portal site but usually only with easy histocom-
patibility barriers (3, 21, 23, 26). Mazzoni et 
al. (17, 18) had positive experiments with pig 
kidneys but these findings were not confirmed 
by Hickman and Terblanche (12). Barker and 
Corriere (1), Fukada et al.(ll), and May et al. 
(15) saw no amelioration of the rejection of 
primary canine kidney homografts that were 
drained into the portal vein. However, Fukada 
et al. (11) thought that sensitization directed to 
a second kidney from the same donor was 
thereby reduced. 
The investigations herein reported failed to 
demonstrate any portal site privilege for pri-
mary transplants either in dogs or pigs. The 
canine results confirmed the negative findings 
of previous workers (1, 11, 15), and extended 
these conclusions to conditions in the dog of 
single-dose or low-dose chronic azathioprine 
treatment. Furthermore, concomitant delivery 
of semisoluble antigen into the portal vein had 
an effect no different from that of systemic anti-
gen, and neither route produced a prolongation 
of survival of transplanted kidneys. The nega-
tive experiments were not different from the 
earlier ones by CaIne et al. (5). 
The results in pigs were different from those 
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observed several years ago by one of us (17,18). 
Failure to reproduce the earlier work might be 
attributable to differences in the pigs in widely 
separated parts of the world, even though the 
breeds were the same. The pig as an experi-
mental animal has been criticized as an unpre-
dictable experimental model. Another possibil-
ity could have been the presence of inadvertent 
experimental bias in the earlier work, in which 
control experiments were carried out at a time 
different from the portal site experiments. 
The importance of concurrent controls in dog 
and pig experiments is also illustrated in the 
studies herein reported. The number of long-
term survivors in untreated mongrel dog recipi-
ents of portal site kidneys was so great that a 
therapeutic effect could have been inferred if 
historical control data had been accepted for 
comparison. Instead, it became clear that al-
most 10% of the untreated animals with homo-
graft drainage through either the portal vein or 
vena cava had survived in excess of 1 month. 
Under minimum treatment, these results 
were improved, both in terms of survival and 
histopathological criteria. Repeated doses of 
azathioprine that have been considered homeo-
pathic by others had an effect. Thus, experi-
ments that impute a zero effect of low-dose 
azathioprine alone upon survival contain a flaw 
in design, at least according to our data. 
The better picture of control data or data 
from low-dose immunosuppression that is 
emerging is in part ascribable to the culling out 
of experiments in which the animals fail to live 
5 full days. In untreated animals, the cause of 
early death was almost always for anesthetic or 
technical reasons. These factors are usually ir-
relevant or confusing in evaluating the antire-
jection effects of the drug or other system being 
tested. Thus, the propriety of removing the ar-
tifacts caused by the earlier deaths seems in-
contestable. 
On the basis of these investigations, it seems 
unlikely that any specific benefit could be ex-
pected in patients from renal transplantation to 
the portal vein. The question that remains is 
whether there really is an amelioration of rejec-
tion in rats and mice. As already mentioned, 
any mitigating effects described to date have 
been small and seen only when there are minor 
histocompatibility barriers. 
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